125072-69-7

Usage

Uses

Used in Pharmaceutical Industry:
Epinortrachelogenin is used as a potential therapeutic agent for its anti-inflammatory and anti-cancer properties. It is being studied for its ability to inhibit the growth of cancer cells by inducing apoptosis and disrupting cell cycle progression, which could lead to the development of new cancer treatments.
Used in Antioxidant Applications:
Epinortrachelogenin is used as an antioxidant, which may help protect cells from damage caused by reactive oxygen species. Its antioxidant activity could be beneficial in the development of treatments for various diseases and conditions associated with oxidative stress.
Used in Antifungal Applications:
Epinortrachelogenin is used as an antifungal agent, potentially effective against various fungal infections. Its antifungal properties could be utilized in the development of new antifungal medications or treatments.

Upstream product

• 124988-57-4 (2R,3S)-2,3-bis(4-benzyloxy-3-methoxybenzyl)-2-hydroxy-4-butanolide 
• 111194-07-1 trans-(+/-)-dihydro-3,4-bis<<3-methoxy-4-(phenylmethoxy)phenyl>methyl>-2(3H)-furanone 
• 116185-13-8 (3S,4S)-3,4-Bis-(4-benzyloxy-3-methoxy-benzyl)-dihydro-furan-2,5-dione 
• 116185-11-6 benzyl 3-[4-(benzyloxy)-3-methoxyphenyl]propanoate 
• 116185-12-7 2,3-bis<<3-methoxy-4-(phenylmethoxy)phenyl>methyl>-butanedioic acid 
• 30034-49-2 β-(4-benzyloxy-3-methoxyphenyl)propionic acid 
• 1135-23-5 3-(4-hydroxy-3-methoxyphenyl)propionic acid 
• 1135-24-6 (E)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid 
• 116185-15-0 dihydro-3-hydroxy-3,4-bis<<3-methoxy-4-(phenylmethoxy)phenyl>methyl>-2,(3H)-furanone 
• 111194-07-1 (3R,4R)-3,4-bis(4-benzyloxy-3-methoxybenzyl)dihydrofuran-2(3H)-one 
• 111266-03-6 (R)-(+)-3-(4-benzyloxy-3-methoxybenzyl)-γ-butyrolactone 
• 72724-00-6 1-(benzyloxy)-4-(bromomethyl)-2-methoxybenzene 
• 336101-59-8 (2R,2'S,4'S)-2-{4-[4-(benzyloxy)-3-methoxybenzyl]-2-(tert-butyl)-5-oxo-1,3-dioxolan-4-yl}-3-[4'-(benzyloxy)-3'-methoxyphenyl]propanoic acid 
• 336101-58-7 (R)-3-(4-Benzyloxy-3-methoxy-phenyl)-2-((2S,4S)-2-tert-butyl-5-oxo-[1,3]dioxolan-4-yl)-propionic acid 

Downstream Products

• 33464-73-2 (-)-O-methyltrachelogenine 
• 146196-54-5 (-)-O-dimethyltrachelogenine 
• 33464-73-2 3,4-bis<(3,4-dimethoxyphenyl)methyl>dihydro-3-hydroxy-2(3H)-furanone 
• 33464-73-2 3,4-bis<(3,4-dimethoxyphenyl)methyl>dihydro-3-hydroxy-2(3H)-furanone 
• 58139-12-1 7-hydroxysecoisolariciresinol 

Relevant academic research and scientific papers

Radical and superoxide scavenging activities of matairesinol and oxidized matairesinol

The radical and superoxide scavenging activities of oxidized matairesinols were examined. It could be assumed that the free benzylic position was important for higher radical scavenging activity. The different level of activity was observed between 7′-oxomatairesinol (Mat 2) and 7-oxomatairesinol (Mat 3). The activity of 8-hydroxymatairesinol was lower than that of matairesinol (Mat 1). The superoxide scavenging activity of the oxidized matairesinols was also demonstrated for the first time. It is assumed that the pKa value of phenol in the oxidized matairesinols affected this activity.

Enantioselective synthesis of (-)-wikstromol using a new approach via malic acid

The total synthesis of (-)-wikstromol, a bioactive α-hydroxylated lactone lignan, from natural malic acid using a consecutive alkylation strategy is presented. First, alkylation of a malic acid ester provided the monobenzyl derivative, which was then converted to an α-substituted dioxolanone. This derivative was reacted in a second alkylation step to a double benzylated dioxolanone, which was transformed to bis-O-benzyl-protected (-)-wikstromol and subsequently to the natural product. Only six steps were required to produce wikstromol in 30% overall yield. A second approach from malic acid, the double alkylation of dienolates from 5-oxo-1,3-dioxolan-4-yl acetic acid derivatives, was not successful. No reaction conditions were found to afford the dienolates. Instead, rapid fragmentation of the dioxolanones to fumaric acid derivatives and pivalaldehyde occurred even at -105 °C, and aldol reaction products with good stereoselectivity were formed. The relative configuration of the major isomer was determined by X-ray structure analysis. By comparison of NMR data it is shown that a previous assignment of the configuration of one of the described aldol products was incorrect.

TOTAL SYNTHESES OF (-)-TRACHELOGENIN, (-)-NORTRACHELOGENIN AND (+)-WIKSTROMOL

The title compounds were obtained by α-hydroxylation of the corresponding α,β-dibenzyl-γ-butyrolactones (lignans of synthetic origin), and were correlated to (+/-)-methyltrachelogenin 9 whose relative structure was definitely established by X-ray cristallography. (-)-Trachelogenin 1 and (-)-nortrachelogenin 12 thus have the (8S,8'S) absolute configuration, whereas (+)-nortrachelogenin 20 (or wikstromol) has the (8R,8'R) absolute configuration.

Total Synthesis of (+/-)-Wikstromol

The antineoplastic prototype lignan natural product wikstromol was synthesized in racemic form by a straightforward sequence involving, as its key transformations,oxidative coupling of a carboxylic acid dianion,generation and stereoselective oxidation of a potassium enolate,and a deprotection step.The overall yield for nine steps is 29percent.Depending on the choice of oxidants for the enolate,considerable modification in the ratio of stereoisomeric products is possible.